Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALDX
#3971
Aldeyra Therapeutics, Inc.
1.7
9
USD
-0.56%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
-0.56%
Mudança mensal
-59.13%
Mudança em 6 meses
-66.48%
Mudança anual
-15.57%
Fechamento anterior
1.8
0
Abrir
1.7
9
Bid
Ask
Mínimo
1.7
9
High
1.7
9
Volume
52
Mercados
Ações
Cuidados de saúde
ALDX
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
47.25 M
58.1 M
58.58 M
58.9 M
59.71 M
60.18 M
—
Valuation ratios
Enterprise value
257.92 M
18.46 M
278.44 M
64.58 M
258.69 M
241.99 M
995.22 M
Price to earnings ratio
—
—
-6.57
-5.53
-5.31
-9.25
-26.83
Price to sales ratio
—
—
—
—
—
-1 164
—
Price to cash flow ratio
—
—
-7.18
-6.88
-6.87
-9.33
-30.19
Price to book ratio
—
—
2.69
1.74
4.18
7.03
10.25
Enterprise value to EBITDA ratio
—
—
—
—
—
-22.35
—
Profitability ratios
Return on assets %
-0.45
-0.25
-0.34
-0.25
-0.53
-0.47
-0.41
Return on equity %
-0.63
-0.28
-0.41
-0.31
-0.79
-0.76
-0.63
Return on invested capital %
-1 273.14
-9 369.38
-24.54 K
-239.61
-324.33
-984.95
—
Gross margin %
—
—
—
—
—
100
—
Operating margin %
—
—
—
—
—
13.2 K
—
EBITDA margin %
—
—
—
—
—
4 047.04
—
Net margin %
—
—
—
—
—
12.66 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.69
19.77
11.78
6.64
5.59
2.58
14.66
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
-0
-0
Solvency ratios
Debt to assets ratio
0.14
0.07
0.08
0
0.15
0
0.18
Debt to equity ratio
0.2
0.08
0.1
0
0.22
0.01
0.27
Long term debt to total assets ratio
0.14
0.07
0.08
0
0.14
0
0.16
Long term debt to total equity ratio
0.19
0.08
0.1
0
0.21
0
0.24
Per share metrics
Operating cash flow per share
—
—
-0.97
-0.51
-0.73
-0.56
-0.56
EBIT per share
—
—
—
—
—
-0.17
-0.17
EBITDA per share
—
—
—
—
—
-0.18
-0.18
Total debt per share
—
—
0.26
0.01
0.26
0
0.28
Cash per share
—
—
3.5
0
2.48
1.17
6.89
Net current asset value per share
—
—
3.1
2.51
1.75
1.2
5.44
Tangible book value per share
—
—
2.59
2.03
1.19
0.74
3.54
Working capital per share
—
—
2.84
2.13
1.44
0.73
3.77
Book value per share
—
—
2.59
2.03
1.19
0.74
3.54
Notícias
AbbVie: Buy Or Sell Ahead Of Q1 Earnings? It's A Buy, But With Caveats (Upgrade) (ABBV)
Aldeyra Therapeutics quita préstamo de US$ 15 milhões com Hercules e encerra linha de crédito
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
H.C. Wainwright rebaixa classificação da Aldeyra após revés com FDA
BTIG mantém recomendação de compra para Aldeyra Therapeutics após revés com FDA
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.10%
E.U.A. - Ações fecharam o pregão em alta e o Índice Dow Jones Industrial Average avançou 0,10%
RBC reitera classificação de ações da Bausch & Lomb após atraso de rival
RBC reiterates Bausch & Lomb stock rating on DED rival delay
FDA rejects Aldeyra’s dry eye disease drug application
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?